NeoAMR- Neonatal AntiMicrobial Resistance

NeoAMR is a research and development programme run by the Global Antibiotic R&D Partnership (GARDP), a joint initiative of DNDi and the WHO, which aims to develop and deliver new treatments for bacterial infections where drug resistance is present or emerging, or for which inadequate treatment exists. The overarching goal of NeoAMR is to develop new improved treatment regimens for the management of neonatal sepsis in settings with high prevalence of multidrug-resistant and extensively drug-resistant pathogens.  Penta is a partner in this project, leveraging its network and experience as a part of NeoAMR research activities.


More details on specific activities can be found at: